Premature Myocardial Infarction: An updated Overview

Corresponding Author:
Dr. Wael Alkhiary,
MBBCH, MSc, PhD student, Mansoura University, Faculty of Medicine, Clinical Pathology Dept Laboratory Hematology and Hemostasis, 35116 - Egypt

Submitting Author:
Dr. Wael Alkhiary,
MBBCH, MSc, PhD student, Mansoura University, Faculty of Medicine, Clinical Pathology Dept Laboratory Hematology and Hemostasis, 35116 - Egypt

Article ID: WMC002597
Article Type: Review articles
Submitted on: 08-Dec-2011, 09:15:29 PM GMT    Published on: 09-Dec-2011, 06:08:30 PM GMT
Article URL: http://www.webmedcentral.com/article_view/2597
Subject Categories: CARDIOLOGY
Keywords: Acute myocardial infarction, Premature myocardial infarction

How to cite the article: Alkhiary W . Premature Myocardial Infarction: An updated Overview . WebmedCentral CARDIOLOGY 2011;2(12):WMC002597

Source(s) of Funding:
No funding source

Competing Interests:
None

Additional Files:
premature myocardial infarction
Premature Myocardial Infarction: An Updated Overview

Author(s): Alkhiary W

Abstract

Although myocardial infarction (AMI) is usually the disease of older people over 45 years of age, an increasing number of younger patients is being recorded. Additionally, AMI in very young patients aged 35 years and younger has been poorly described. Besides atherosclerotic coronary artery disease, non-atherosclerotic coronary artery diseases or hypercoagulability should be considered for young cases of myocardial infarction. The predominance of angiographic single-vessel disease and myocardial infarction with normal coronary arteries in these patients primarily suggest that premature myocardial infarction probably result from a rapid progressive event, such as thrombosis or plaque rupture, rather than a gradually evolving process, such as atherosclerosis. In the future, atherosclerotic burden, hemostatic function, characterization of stressors and inflammation will be important targets for research in this group of patients.

An Overview

Advancing age is a well-acknowledged risk factor for AMI in both men and women. Although myocardial infarction (MI) is usually the disease of older people over 45 years of age, an increasing number of younger patients is being recorded presenting with premature myocardial infarction (1). It is estimated that about less than 10% of individuals presenting with documented CAD are Although CHD is an uncommon entity in young patients, it constitutes an important problem for both the patient and the physician because of the devastating effect of this disease. More importantly, these patients have different risk factor profiles, clinical presentations, and prognoses than older patients. Myocardial infarction presenting at a young age shows a different clinical, angiographic findings and pathophysiological profile compared to older (2, 6-11). Additionally, MI in very young patients (aged 35 years and younger) has been poorly described (12).

Traditional risk factors of CAD seen in the elderly age group do not apply to younger age group (13-15). Young patients tend to have less extensive atheromatous lesions and the contribution of prothrombotic and inflammatory indices may be particularly implicated in the initiation and development of such atherosclerotic lesions (8, 9). It is also known that the long-term prognosis and functional status of young patients who have acute myocardial infarction (MI) is not benign (2, 6, 16).

Myocardial Infarction with Normal Coronary Arteries (MINCA) is an important subgroup of myocardial infarction in young patients with a frequency of at least 3-4% of all myocardial infarctions. The proposed mechanisms for MINCA include coronary vasospasm, coronary thrombosis in situ or embolization from a distal source with spontaneous lysis, cocaine abuse, viral myocarditis, aortic dissection, hypercoagulable states, autoimmune vasculitis and carbon monoxide poisoning (17).

Moreover, the predominance of angiographic single-vessel disease in these young patients primarily suggest that premature myocardial infarction probably result from a rapid progressive event, such as thrombosis or plaque rupture, rather than a gradually evolving process, such as atherosclerosis, and thus substantiate the need for an intense and aggressive approach directed towards primary and secondary preventions of premature cardiovascular disease (11). It is unknown whether the incidence of MI at an early age incorporates a grave prognosis or warrants an approach that is different from that used in older patients (12). Nevertheless, it is unclear whether AMI at the younger age can be considered an autonomous representation of the infarct process or a more premature and accelerated expression of the same atherosclerotic process witnessed in older population. Attempts to study this aspect have been stalled by the relative infrequency of AMI in the young, as well as the inconsistencies regarding the definition of youth (10).

Intravascular thrombogenesis is influenced by a complex interplay of procoagulant, anticoagulant, fibrinolytic, endothelial damage/dysfunction and inflammatory factors. Abnormalities of these biological systems would contribute to coronary artery disease presenting at a young age (9). Clinical features suggesting underlying arterial thrombophilia in
Premature CAD include: 1) Previous arterial thrombosis and age $\leq$ 50 (male) or $\leq$ 55 (female); 2) Age $\leq$ 55 (male) or $\leq$ 60 (female) with no other traditional risk factors present; 3) No significant coronary stenosis on angiography; and 4) Age $\leq$ 55 (male) or $\leq$ 60 (female) with strong family history (defined as at least one first-degree relative affected at age 50 years if male or 55 years if female) (4,18). In the future, atherosclerotic burden, hemostatic function, characterization of stressors and inflammation will be important targets for research in this group of patients (17).

References

Reviews

Review 1

Review Title: Premature Myocardial Infarction: An updated Overview

Posted by Mr. Rui M Almeida on 10 Dec 2011 06:30:05 PM GMT

| 1 | Is the subject of the article within the scope of the subject category? | Yes |
| 2 | Are the interpretations / conclusions sound and justified by the data? | Partly |
| 3 | Is this a new and original contribution? | No |
| 4 | Does this paper exemplify an awareness of other research on the topic? | Yes |
| 5 | Are structure and length satisfactory? | No |
| 6 | Can you suggest brief additions or amendments or an introductory statement that will increase the value of this paper for an international audience? | No |
| 7 | Can you suggest any reductions in the paper, or deletions of parts? | No |
| 8 | Is the quality of the diction satisfactory? | Yes |
| 9 | Are the illustrations and tables necessary and acceptable? | Yes |
| 10 | Are the references adequate and are they all necessary? | Yes |
| 11 | Are the keywords and abstract or summary informative? | Yes |

Rating: 4

Comment:
Despite drug-induced AMI being not a common event, still is a cause of growing interest and should have been mentioned.

Competing interests: No

Invited by the author to make a review on this article? : No

Experience and credentials in the specific area of science:
Just by reading the literature

Publications in the same or a related area of science: No

How to cite: Almeida R. Premature Myocardial Infarction: An updated Overview [Review of the article ‘Premature Myocardial Infarction: An updated Overview ’ by ], WebmedCentral 2011;2(12):WMCRW001228
Disclaimer

This article has been downloaded from WebmedCentral. With our unique author driven post publication peer review, contents posted on this web portal do not undergo any prepublication peer or editorial review. It is completely the responsibility of the authors to ensure not only scientific and ethical standards of the manuscript but also its grammatical accuracy. Authors must ensure that they obtain all the necessary permissions before submitting any information that requires obtaining a consent or approval from a third party. Authors should also ensure not to submit any information which they do not have the copyright of or of which they have transferred the copyrights to a third party.

Contents on WebmedCentral are purely for biomedical researchers and scientists. They are not meant to cater to the needs of an individual patient. The web portal or any content(s) therein is neither designed to support, nor replace, the relationship that exists between a patient/site visitor and his/her physician. Your use of the WebmedCentral site and its contents is entirely at your own risk. We do not take any responsibility for any harm that you may suffer or inflict on a third person by following the contents of this website.